Treatment-Responsive Acute Graft-versus-Host Disease After Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes

Blog
Article

A recent study investigated the incidence and clinical outcomes of acute graft-versus-host disease following post-transplantation cyclophosphamide-based prophylaxis in hematopoietic cell transplantation.

A recent study investigated the incidence and clinical outcomes of acute graft-versus-host disease following post-transplantation cyclophosphamide-based prophylaxis in hematopoietic cell transplantation.

A recent study investigated the incidence and clinical outcomes of acute graft-versus-host disease following post-transplantation cyclophosphamide-based prophylaxis in hematopoietic cell transplantation.

A recent study, published in Transplantation and Cellular Therapy, investigated the incidence and clinical outcomes of acute graft-versus-host disease (aGVHD) following post-transplantation cyclophosphamide (PTCy)-based prophylaxis in hematopoietic cell transplantation (HCT). This work, from researchers at The University of Minnesota, assessed a cohort of 196 adult and pediatric patients who underwent allogeneic HCT with PTCy, tacrolimus and mycophenolate mofetil (MMF) prophylaxis. The study identified the distribution of aGVHD into steroid-sensitive (SS), steroid-dependent (SD) and steroid-resistant (SR) categories, exploring their respective clinical outcomes. The findings indicate that the overall incidence of aGVHD requiring systemic corticosteroids was 16%, with the majority classified as SS.

A notably lower incidence of SR aGVHD in patients receiving PTCy-based prophylaxis compared to non-PTCy regimens was found. Specifically, only 4.6% of patients developed SR aGVHD, compared to the 14.7% observed in previous studies using different prophylactic approaches. Among the 54 patients who developed aGVHD, 41% were SS, 31% SD, and 28% SR. The clinical outcomes show that SS and SD patients had similar two-year overall survival rates (77% and 75%, respectively), which were comparable to those without aGVHD (81%). Conversely, the SR group exhibited the poorest outcomes, with a significantly lower two-year overall survival rate of 20% and higher non-relapse mortality primarily due to GVHD.

These findings demonstrate the effectiveness of PTCy-based prophylaxis in reducing the incidence of severe, treatment-resistant aGVHD, thus improving patient outcomes post-transplant. It highlights the importance of monitoring and managing aGVHD treatment responses to enhance survival rates and reduce complications. The researchers advocate for further studies to confirm these findings and to optimize GVHD prophylaxis protocols, particularly focusing on reducing SR aGVHD incidences and improving therapeutic strategies for managing this condition.

Reference

Herzog S, Shanley R, Holtan SG, MacMillan ML, Weisdorf DJ, Jurdi NE. Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes. Transplant Cell Ther. Published online May 9, 2024. doi.10.1016/j.jtct.2024.05.007

Recent Videos
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content
Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD

Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD

American Society for Transplantation and Cellular Therapy
September 26th 2024
Article

These findings demonstrate the potential risks associated with CNI-based immunosuppression in stem cell transplantation without concurrent strategies to eliminate alloreactive T cells.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Lower-Risk MDS Population Has Enduring RBC-TI Following Imetelstat Therapy

Ashling Wahner
September 8th 2024
Article

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.

FDA Approves Bortezomib Injection in Multiple Myeloma/MCL

Ariana Pelosci
September 6th 2024
Article

A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.

The Best of CAR T at the 2024 Tandem Meetings

The Best of CAR T at the 2024 Tandem Meetings

American Society for Transplantation and Cellular Therapy
August 30th 2024
Article

The Best of CAR T at the 2024 Tandem Meetings Webinar Series, which aired on June 27, 2024, aimed to provide a comprehensive overview of the latest advancements and research in CAR T cell therapy.